RxDoctor Payments Data

Mae Anne Sepulveda, MD

Family Medicine · San Antonio, TXNPI 1881825719

Payments from drug & device makers

$1,440in general payments, 2019–2025

Across 89 payments — averaging $16.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$333
  • Boehringer Ingelheim$202
  • Sanofi-aventis U.S. LLC$195
  • Astellas Pharma US Inc$158
  • AstraZeneca$104
  • AbbVie$100
  • plus $348 from 8 others

What the payments were for

  • Food & beverage$1,34193%
  • Education$997%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,440 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$124,461
Medicare patients
222
Services billed
3,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide139$231,108
JardianceEmpagliflozin82$106,701
MounjaroTirzepatide86$96,475
EliquisApixaban87$92,234
JanuviaSitagliptin Phosphate71$81,061
FarxigaDapagliflozin Propanediol23$28,077
XareltoRivaroxaban26$27,075
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$15,751
TrulicityDulaglutide14$15,069
SymbicortBudesonide/Formoterol Fumarate21$12,193
MyrbetriqMirabegron12$10,469
Tresiba Flextouch U-100Insulin Degludec16$9,406
Repatha SyringeEvolocumab13$8,639
PremarinEstrogens, Conjugated16$7,615
Spiriva RespimatTiotropium Bromide14$7,106

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$333$231,108139 claims
Boehringer IngelheimJardiance, Spiriva Respimat$202$113,80796 claims
Lilly USA, LLCMounjaro, Trulicity$50$111,544100 claims
MerckJanuvia$91$81,06171 claims
AstraZenecaFarxiga, Symbicort$104$40,27044 claims
GSKTrelegy Ellipta, Breo Ellipta$20$21,86433 claims
Astellas Pharma US IncMyrbetriq$158$10,46912 claims
AbbVieSynthroid$100$4,35932 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in San Antonio

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →